Four years ago, a group of cardiovascular nurses and technicians from St. Luke’s Medical Center Milwaukee came together to discuss the value of continuing education, the difficulty and expense of obtaining CEUs, and the benefits and limitations of national meetings. This group of professionals began to create a list detailing what they believed would constitute the ideal meeting. The group decided the ideal meeting would be interactive and hands-on. The hands-on sessions would be proctored by experts that would explain the limitations of technology while identifying the pearls learned from ycontinue reading
Morton Kern, MD
Suite 100, Malvern PA 19355
Fax: (866) 896-8762
Cath Lab Digest will, on occasion, publish an article that looks at an accepted issue or standard in an outside-the-box kind of way. We are fortunate to have such an article by Dr. David Allie this month, titled: Vascular Access Site Hemostasis: ‘An Endovascular Surgeon’s Perspective’ Manual Compression May Not Be Benign! Dr. Allie compares the state of today’s vascular closure devices with the beginning of the coronary stent era, and calls for more industry investment in an ideal vascular closure device.
By virtue of his background as a vascular surgeon, one important implicacontinue reading
Boston Scientific Announces FDA Clearance for Peripheral Cutting Balloon Microsurgical Dilatation Devices
Device Dilates Lesions at Lower Pressures than Traditional Angioplasty
Boston Scientific Corporation has received clearance from the U.S. Food and Drug Administration (FDA) to market its Peripheral Cutting Balloon microsurgical dilatation device in the United States. The Company will launch the device immediately.
The Peripheral Cutting Balloon device features tiny, longitudinally mounted atherotomes (microsurgical blades) on the surface of an angioplasty balloon and willcontinue reading
What is the Impella® Recover® LP 2.5 System?
The Impella Recover LP 2.5 device is a percutaneous ventricular unloading catheter. This is a 12-French catheter, placed in the left ventricle, which utilizes a transaxial flow pump to transfer blood from the left ventricle into the ascending aorta. The pump can deliver as much as 2.5 liters of blood per minute. Essentially, the Recover LP 2.5 System increases cardiac output, thereby increasing end-organ perfusion. In addition, by unloading the left ventricle, it reduces myocardial workload and oxygen consumption. We suspect that thiscontinue reading
What type of procedures are performed at your facility?
At Charlotte Regional Medical Center, we perform diagnostic and interventional procedures, including EP studies, tilt table studies, cardioversions, ablations, automatic implantable cardioverter defibrillator (AICD) and pacer implants, PTCA, stents, Rotoblator® (Boston Scientific Corporation, Maple Grove, MN), intra-aortic balloon pump (IABP), brachytherapy, FilterWire (Boston Scientific), AngioJet® (Possis Medical, Inc., Minneapolis, MN) and intravascular ultrasound (IVUS). Our lab performs an estimated 3,000 cases per year wcontinue reading
When endovascular techniques came about almost two decades ago, I was just finishing my training, and I knew I wanted to be involved, so I went to the cath lab. I still spend a great deal of time there, and have for more than 15 years. There is a soft spot in my heart for the cath lab professional. Surgeons know how important it is to have a good surgical tech, and when I went into the cath lab, I wasn’t trained only by cardiologists, but by several very good and seasoned cath lab technologists, including Chris Hebert and Gary Chaisson, who have over 40 years of experience combined. They actcontinue reading
Dr. Heldman was the first to demonstrate effective reduction of coronary restenosis in an animal model with a prototype drug eluting stent. His clinical interests include the treatment and prevention of coronary restenosis; complex coronary interventions, coronary stenting, diseases of the aorta and peripheral vascular disease. His research interests include coronary stent design; coronary local drug delivery for treatment and prevention of restenosis; cardiovascular gene therapy; stem cell myogenesis; and cardiac magnetic resonance imaging (MRI). Dr. Heldman has published extensively in scontinue reading